"The results are durable, but of course we want to see that durability continue." – Andrea Cercek, MD, section head, colorectal cancer, Memorial Sloan Kettering Cancer Center
Immunotherapy Alone Spares dMMR Rectal Cancer Patients the Lasting Effects of Standard Treatment, Says MSK's Andrea Cercek
In the second part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains how patients are monitored after a complete response to dostarlimab, what longer follow-up needs to show, and how avoiding chemoradiation and surgery changes patients' lives.
FDA's accelerated approval of Jemperli (dostarlimab-gxly) in MSI-H/dMMR locally advanced rectal cancer rests on a 12-month endpoint. For patients and physicians, the next question is what happens after that.
In the pivotal AZUR-1 trial, the rate of clinical complete response sustained for 12 months (cCR12) was 47% by independent central review in 116 evaluable patients and 68% by investigator assessment in 144 evaluable patients. At a median follow-up of 26.3 months,
In the second part of a two-part video interview with BioPharm International®,
Patients are watched closely, Cercek said, with serial MRI and flexible sigmoidoscopy "just about every four months." They are also monitored for clinical signs and symptoms of recurrence.
She said the trial design already builds in a measure of durability. "The endpoint was a cCR12 or what was a clinical complete response that was already sustained for 12 months," she said. "So already the patients achieved a complete response and then had no tumor recurrence for 12 months."
"Even longer follow-up, we have not seen any recurrences in AZUR-1 in the patients that achieved a clinical complete response," Cercek said. Freedom from local recurrence, disease-free survival, and overall survival are still maturing and will be reported later, she noted.
"But we do already have a very good sense of durability of response and certainly in our study as well, 96% durability of response of clinical complete responses," she said.
"They really function completely normally, which is, I think the most rewarding thing of all." – Andrea Cercek, MD, section head, colorectal cancer, Memorial Sloan Kettering Cancer Center
What changes for patients who avoid chemoradiation and surgery?
Cercek pointed out that the approval came from a single-arm registrational study. Randomizing patients to radiation was felt to be unethical given how strongly tumors responded to immunotherapy alone, she said, and the endpoint itself is "incredibly patient-centric."
Standard tri-modality therapy can leave lasting effects. About 30% of patients need a permanent colostomy, Cercek said, and radiation and surgery can cause infertility as well as bowel, bladder, and sexual dysfunction. Chemotherapy adds a risk of neuropathy. With dostarlimab alone, "there's really no toxicity in terms of the pelvic floor, in terms of any bowel, bladder, or sexual dysfunction," she said.
For younger patients, that has made family planning possible. "So we've had babies in our investigator-initiated study now, five babies have been born to patients post completion of immunotherapy with dostarlimab," Cercek said. Patients have had spontaneous pregnancies and normal vaginal deliveries, and young women treated with immunotherapy alone do not enter menopause, she said.
The benefit extends to older patients too, including several treated in their late 80s and early 90s. After standard treatment, most patients have to manage their bowels and know where a bathroom is at any given time, she explained. "And this is not an issue now with the patients that received immunotherapy."
Check out the first part of this two-part interview
About the Speaker
Andrea Cercek, MD, section head, colorectal cancer, Memorial Sloan Kettering Cancer Center
Andrea Cercek is a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), where she is section head of colorectal cancer and founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancers. Her research focuses on novel therapies for early-stage disease, including immunotherapy, and on defining the causes of and improving treatment for early-onset colorectal cancer. She earned her MD at New York Medical College and completed an internal medicine residency at NewYork-Presbyterian/Weill Cornell Medical Center and a hematology/oncology fellowship at MSK.
Related to this article









